Latch, Inc. (LTCH): Nasdaq/NYSE listing notice — Latch gets Nasdaq extension to Aug 4, 2023 for listing compliance; still faces delisting risk

Latch, Inc.

Nasdaq Hearings Panel granted continued listing on Global Select Market conditional on filing by Aug 4, 2023.
Company must file restated financials for 2019-2022, delinquent Q2/Q3 2022 10-Qs, and Q1 2023 10-Q.
Received additional non-compliance notice (April 6, 2023) for failure to file 2022 10-K; no immediate trading impact.
If compliance not regained by Aug 4, 2023, common stock and warrants subject to delisting.
Company is restating financials for 2019, 2020, 2021, and Q1 2022 due to ongoing restatement.

item 3.01 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Latch, Inc. received a nasdaq hearing update notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: hearing update
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

April 6, 2023, the Company received an additional notice from the Staff (the “April Notice”) notifying the Company that it is not in compliance with the Listing Rule as a result of its failure to timely file the Annual Report with the SEC. The April Notice has no immediate effect on the listing or trading of the Company’s shares of common stock or warrants. However, if the Company fails to regain compliance with the Listing Rule by August 4, 2023, the Company’s shares of common stock and warrants will be subject to delisting from Nasdaq. There can be no assurances that the Company will be able

View on SEC.gov

Browse all listing & compliance notices →

Latch, Inc. filing history →

Source: SEC EDGAR

accession 0001826000-23-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.